519 related articles for article (PubMed ID: 14565787)
1. Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.
Cvetkovic RS; Perry CM
Drugs Aging; 2003; 20(12):919-47. PubMed ID: 14565787
[TBL] [Abstract][Full Text] [Related]
2. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.
Rouland JF; Le Pen C; Gouveia Pinto C; Berto P; Berdeaux G
Pharmacoeconomics; 2003; 21(3):201-13. PubMed ID: 12558470
[TBL] [Abstract][Full Text] [Related]
3. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
4. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
Balfour JA; Wilde MI
Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy.
Shin D
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S163-8. PubMed ID: 10665519
[TBL] [Abstract][Full Text] [Related]
6. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension.
Holló G; Bozkurt B; Irkec M
Expert Opin Pharmacother; 2009 Aug; 10(12):2015-24. PubMed ID: 19618994
[TBL] [Abstract][Full Text] [Related]
7. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
March WF; Ochsner KI
Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
9. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.
Croxtall JD; Scott LJ
Drugs Aging; 2009; 26(5):437-46. PubMed ID: 19552495
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.
Sall K
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S155-62. PubMed ID: 10665518
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Sugrue MF
Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
14. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
Ormrod D; McClellan K
Drugs Aging; 2000 Dec; 17(6):477-96. PubMed ID: 11200308
[TBL] [Abstract][Full Text] [Related]
15. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
16. Brinzolamide.
Iester M
Expert Opin Pharmacother; 2008 Mar; 9(4):653-62. PubMed ID: 18312166
[TBL] [Abstract][Full Text] [Related]
17. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group.
Silver LH
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S141-5. PubMed ID: 10665516
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients.
Wang TH; Huang JY; Hung PT; Shieh JW; Chen YF
J Formos Med Assoc; 2004 May; 103(5):369-73. PubMed ID: 15216404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
